Document is current
Any future updates will be listed below
-
Authors
Olivieri, Chiara
Tibaldi, Tommaso
Berni, Alessandro https://orcid.org/0000-0002-6412-1288
Eandi, Chiara Maria
Neri, Giovanni
Fai, Antonio
Viggiano, Pasquale https://orcid.org/0000-0002-0323-967X
Marolo, Paola
Bandello, Francesco
Reibaldi, Michele
Borrelli, Enrico https://orcid.org/0000-0003-2815-5031
- License Information
-
More Information
Article History
Received: 27 January 2025
Revised: 30 May 2025
Accepted: 27 June 2025
First Online: 9 July 2025
Competing interests
: EB is a member of the Eye editorial board. FB: Abbvie, Alimera, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, Ntc Pharma, Oxurion Nv, Sifi. MR: Abbvie (C), Bayer (C), Hofmann La Roche (C), Novartis (C), Zeiss (C); EB: AbbVie; Bayer; Espansione; EyePoint; Novartis; Ocular Therapeutix; Hofmann La Roche; Zeiss. Other authors: none.
